title: Pharmacokinetics and pharmacodynamics of antibacterial and antifungal agents in adult patients with thermal injury: a review of current literature.
abstract: Patients with significant thermal injury are at a high risk for developing bacterial and fungal infections due to the loss of protective integument and often require lengthy treatment courses with anti-infective agents. Dosing of these agents in the burn population is challenging as these patients experience changes in their physiology around 48 hours postinjury. These changes include increased cardiac output, increased blood flow to the kidneys and liver, and decreased albumin production. These alterations in the physiology can lead to an increased drug clearance, higher volumes of distribution, and increased or decreased total drug exposure. Currently, there are no guidelines describing the most ideal method of dosing anti-infectives in this population, and most studies that have been published include only a small number of patients. The purpose of this review is to summarize the existing literature regarding the pharmacokinetics and pharmacodynamics of antibiotics and antifungal agents in the burn population and to provide dosing suggestions whenever possible. Not all antibiotics and antifungal agents have been studied, and further research is needed in this area in order to provide optimal care for patients with thermal injury.
authors.affiliation: From the *Parkland Health and Hospital System, Parkland Memorial Hospital, Dallas, Texas; †Sinai-Grace Hospital, Detroit, Michigan; and ‡Detroit Receiving Hospital, Detroit Medical Center, Michigan.
authors.forename: Jessica K
authors.initials: JK
authors.lastname: Ortwine
authors.forename: Jason M
authors.initials: JM
authors.lastname: Pogue
authors.forename: Janie
authors.initials: J
authors.lastname: Faris
mesh_terms: D000328:Adult; D000700:Analgesics / Q000493:pharmacokinetics* / Q000494:pharmacology; D000890:Anti-Infective Agents / Q000493:pharmacokinetics* / Q000494:pharmacology; D000935:Antifungal Agents / Q000494:pharmacology* / Q000627:therapeutic use; D002056:Burns / Q000188:drug therapy / Q000503:physiopathology*; D004334:Drug Administration Schedule; D006801:Humans; D007166:Immunosuppressive Agents / Q000493:pharmacokinetics; D003473:Neuromuscular Nondepolarizing Agents / Q000493:pharmacokinetics
chemical_list: D000700:Analgesics; D000890:Anti-Infective Agents; D000935:Antifungal Agents; D007166:Immunosuppressive Agents; D003473:Neuromuscular Nondepolarizing Agents